t(6;9)(p23;q34) is a rare recurring cytogenetic aberration resulting in the formation of a chimeric DEK/NUP214 (formerly DEK/CAN) fusion gene on the der(6) chromosome. This translocation has been reported in de novo acute myeloid leukemia (AML), AML preceded by myelodysplastic syndromes (MDS), and in AML which has evolved following prior chemotherapy exposure. [1] [2] [3] [4] Given the rarity of this particular subgroup of AML, previous reports attempting to describe the incidence, associated clinical features, and prognosis have been based on small patient cohorts, leaving some uncertainty about the nature of t(6;9) AML. [1] [2] [3] [4] In order to better define this syndrome, a retrospective study of five Cooperative Groups databases (Southwest Oncology Group (SWOG), Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group (ECOG), Childrens Oncology Group (COG) including the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)) was conducted.
Data from patients enrolled on 20 treatment-completed protocols during 1987 to 2002 were collected. Sixty-nine cases (0.9%) of AML or MDS patients with the t(6;9) cytogenetic abnormality were identified among 7690 patients with evaluable karyotypes. Clinical and pretreatment laboratory features for t(6;9) patients are presented in Table 1 ; ages ranged from 2 to 66 years (median ¼ 23), emphasizing the younger age usually associated with t(6;9) AML. 1 Of 5454 patients on studies for adults, 38 (0.7%) had t(6;9) compared to 31 (1.4%) of 2236 on pediatric studies. The relatively high percentage of children in this analysis, compared with the general population, likely reflects the fact that more children are enrolled on US clinical protocols than adult patients. Moreover, the apparent male predominance in the adult cohort (71%) was not found to be statistically significant (P ¼ 0.06). The 6;9 translocation was the sole clonal karyotypic aberration in 61 of 69 patients (88%); only four pediatric and four adult cases (12%) had secondary anomalies. Three patients (5%) had complex translocations involving three or four chromosomes (46,XX,t(3;6;9)(p21; p23;q34); 46,XY,t(6;22;9)(p23;q11.2;q34); 46,XY,der(6)(9q34-9q34::6p23-cen-6q15::6p25-6p25),der(9)(9pter-cen-9q34:: 6p23-6p25::6q15-6qter)); an incidence similar to other common leukemia translocations. 1 Pediatric and adult t(6;9) patients had similar percentages of blood and bone marrow blasts, and platelet counts (Table 1) ; however, pediatric patients had lower hemoglobin levels (P p0.001) and tended to have higher white blood cell (WBC) counts (P ¼ 0.14) than adults. In fact, the presenting WBC in adults with t(6;9) is lower than seen in AML in general. 5 Thirty (97%) of 31 children and 25 (66%) adults presented with de novo AML. Our t(6;9) cohort showed no FAB subtype specificity; however, the distribution mirrors AML in general. Increased bone marrow basophilia, defined as X2% in the current study, was detected in 12 of 27 patients (44%), confirming a degree of basophilia higher than that generally observed in AML. [1] [2] [3] [4] Auer rods were observed in six (32%) of 19 patients and data on dysplasia were available in 12 adults, of which eight (67%) showed granulocytic, megakaryocytic, or multilineage dysplasia, a finding usually associated with an unfavorable prognosis. Immunophenotype data of 18 adult patients showed that the leukemic blasts were positive for CD13, CD33, and HLA-DR in all 18 patients. CD38 and CD45 were positive in all tested cases, 12 and 17 cases, respectively. In addition, the leukemic blasts were CD34 þ in 13/18 (72%) patients and CD15 þ in 11/17 (65%) patients. Collectively with the reported literature, 1-4 the morphology and immunophenotyping studies are useful in the determination of immature myeloid lineage of t(6;9) AML, but they are not sufficiently specific enough to identify a cytogenetically defined leukemia subtype.
To explore FLT3-activating mutation status, we used singlestranded conformational polymorphism analyses to evaluate 31 t(6;9) samples for FLT3 internal tandem duplications (ITDs) in exons 14 and 15, and FLT3 point mutations in exon 20 as described. 6 Eleven of 16 children (69%) and 11 of 15 adult patients (73%) had FLT3 ITDs. None of these 31 patients harbored point mutations, deletions, or insertions in the tyrosine kinase domain (exon 20). Our 71% incidence of FLT3 ITDs in t(6;9) patients corresponds to previous reports in which a small number of t(6;9) patients were studied 3, 4, 7 and is clearly elevated compared to the incidence observed in AML in general. 6, 7 Unfortunately, a comparison of the t(6;9) AML patients with and without FLT3 mutations with outcome was not conclusive because of the small number of samples without FLT3 ITDs (results not shown).
Although not the focus of this study, clinical response was evaluated for 62 t(6;9) patients with previously untreated AML or MDS (Table 1 ). Overall, 65% of patients, 71% of pediatric cases and 58% of adults, achieved complete remission (CR), comparing similar to the CR rates of the intermediate, 76% (CI 71-81%) and unfavorable, 55% (CI 48-63%) groups in the SWOG/ECOG S9034/E3489 younger adult AML study. 8 Overall survival (OS) ( Figure 1 ) and disease-free survival (DFS) (not shown) of pediatric and adult cases were not significantly different (OS, P ¼ 0.34; DFS, P ¼ 0.48), nor was age a prognostic factor when examined as a continuous variable. The 5-year survival estimate was 28% (95% CI [12%, 44%]) for pediatric patients vs 9% (95% CI [0%, 19%]) for adult patients. Higher peripheral blasts, marrow blasts, and WBC were predictive of shorter OS even after adjusting for age (P ¼ 0.007, P ¼ 0.003, and Po0.0001 respectively). When using multivariate analysis for OS, only WBC remained statistically significant. For DFS, only higher marrow blasts were predictive of shorter DFS (P ¼ 0.014). The OS of t(6;9) adults in this study (9%) was similar to the 5-year OS of 12% reported for the unfavorable group in the SWOG/ECOG S9034/E3489 younger adult AML study 8 (excluding the 10 t(6;9) cases in that series), emphasizing the very poor prognosis for this translocation-specific leukemia (Figure 1) . 1 Hematopoietic stem cell transplantation (SCT) was reported for 18 patients (27%): 11 allogeneic, six autologous, and one unknown. Although SCT data collection was imperfect, lacking disease status at SCT and duration from diagnosis to SCT, an exploratory analysis of this small cohort suggested that allogeneic SCT might be associated with better OS than no SCT (hazard ratio (HR) 0.33 after SCT, 95% CI 0.13-0.85), whereas autologous SCT might not (HR 1.44 CI 0.60-3.45), a finding echoed by other 'poor risk' cytogenetics. 8 In general, the results could not be completely explained by differences in other prognostic factors (age, WBC, and peripheral blood and marrow blast percentages) used in a multivariate analysis. Although no longer significant owing to limited power, there is still a trend toward better OS for allogeneic SCT compared to no SCT (hazard ratio (HR) 0.51 after SCT, 95% CI 0.19-1.39). Similar results were found using DFS as the end point. Moreover, Garçon et al. 4 reported that t(6;9) patients who achieved prolonged molecular remission fared much better compared to their counterparts with persistent DEK/NUP214 positivity, who succumbed to their disease, implying a pivotal role for minimal residual disease detection in managing t(6;9) patients. We like to emphasize that finding conclusive differences in outcome was not the intention of the analysis; nevertheless, the results of AML trials have not shown great differences in results over the years. Therefore, it is unlikely that the poor outcome of these t(6;9) patients is related to the specific treatment studies (or databases) from which the patient data were extracted. What is apparent is that to improve the outcome for t(6;9) and other rare AML subtypes, there is, of course, a need for improved novel therapies and prospective, protocol-driven investigations with standardized data collection procedures and Seven adult pts are excluded from the outcome analyses owing to (a) previous treatment before study registration (four pts previously treated for AML and one pt previously treated for MDS), (b) one pt for lack of follow-up information, and (c) one pt who received no treatment after study registration. These pts are excluded from the analysis of response to provide a more homogeneous adult pt group for comparisons. e Estimated median (in months) and 95% confidence intervals are shown in the table. f The pt described in footnote d (c) is included in the analysis of OS. For OS and DFS, comparisons between groups were based on the log-rank test, and analyses of prognostic factors were based on proportional hazards (PH) regression models.
g Because relapsed pts may have received transplant, they are included in this analysis, except for one who did not receive protocol pretreatment. Time-dependent covariates were used in the PH analysis of patients receiving transplant. All P-values are two-tailed. Abbreviation: AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; DFS, disease-free survival; FLT 3 ITD, FLT3 internal tandem duplications; Hgb, hemoglobin; MDS, myelodysplastic syndrome; OS, overall survival; PB, peripheral blood; SCT, stem cell transplantation; WBC, white blood cell.
perhaps molecular monitoring among the various centers or cooperative groups involved.
In closing, we report the largest t(6;9) patient cohort to date confirming and refining consistent t(6;9) pathological features including increased basophilia, single or multilineage dysplasia in adult patients, variable FAB morphology, a CD13 þ , CD33 þ , CD38 þ , CD45 þ , and HLA-DR þ immunophenotype, and a high incidence (71%) of FLT3 internal tandem duplications. Furthermore, the low incidence of secondary aberrations may be important for targeted therapeutic options in the future. Like all retrospective studies, data collection procedures were discordant among the Groups, complicating the analyses; nevertheless, our study objective is to raise awareness of this very poor risk AML subtype that tends to be more common in younger patients. Accordingly, t(6;9) AML may warrant a prospective multi-center investigation of aggressive and/or novel therapeutic strategies, including allogeneic SCT for patients with an HLA-matched donor, and perhaps because of the presence of CD33 and FLT mutations, the addition of anti-CD33-based therapies plus a FLT3 inhibitor for patients without suitable donors. Finally, to facilitate scientific collaboration to accomplish such an initiative, we support the proposal of adding AML with t(6;9)(p23;q34), DEK/NUP214, as a separate disease entity to the World Health Organization (WHO) Classification of Hematological Malignancies. 3, 9 Reply to Kremer M et al., The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis The current approach to detect JAK2 V617F mutation in patients with chronic myeloproliferative disorders (CMPD) revealed the molecular category of this disease entity and related diseases. 1, 2 Kremer et al. 3 found JAK2 V617F mutation in three of four patients with myelodysplastic (MDS)/myeloproliferative (MPD) diseases, whereas none of 25 patients with MDS with myelofibrosis showed the mutation. They further stated that Figure 1 Estimated probabilities of overall survival of t(6;9) adult and pediatric cases compared with SWOG/ECOG S9034/E3489 younger adult AML study 8 unfavorable risk cytogenetics subgroup. Table 1 describes the t(6;9) patients included in this analysis.
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